Updates in ATTR Cardiac and Neurological Amyloidosis: What's new and exciting for 2022 and beyond.

Thank you

This live web event has ended. Thank you for attending.

Description

Please join us on Friday, October 28th at 12:00p ET for a two-part webinar "Cardiac and Neurologic Manifestations of Hereditary Transthyretin Amyloidosis: This webinar will cover the cardiac and neurologic manifestations of hereditary amyloidosis, diagnostic strategies, and the evolving landscape of therapeutics and their impact on the disease. Specific areas of foci include monitoring for disease progression, effects on quality of life, and recent data on novel transthyretin gene silencers."

The ATTR Cardiac portion of the webinar will be presented by Dr. Frederick Ruberg and Dr. Omar Siddiqi. The updates in ATTR Neurological Amyloidosis will be presented by Dr. Michelle Kaku and Dr. Vincent Lau. Once the presentation is complete the doctors will answer questions in our live Q & A.

Sponsored by Alnylam and the Amyloidosis Foundation.

Contributors

Frederick L. Ruberg, MD

Frederick L. Ruberg, MD is the Thomas J. Ryan Professor of Cardiovascular Medicine and Professor of Radiology at Boston University (BU) Chobanian & Avedisian School of Medicine and Chief, Section of Cardiovascular Medicine at Boston Medical Center (BMC). Dr. Ruberg attended the University of Pennsylvania Perelman School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center in Boston. Committed to research mentorship, he directs Workforce Development for the Boston University Clinical and Translational Science Institute (CTSI) and serves as Senior Associate Editor of Circulation: Cardiovascular Imaging. Dr. Ruberg is a Fellow of the American Heart Association and a member of the Association of University Cardiologists. His clinical and research expertise primarily involves cardiac imaging and infiltrative heart disease focused on improving the recognition and care of patients with cardiac amyloidosis, particularly that owing to the hereditary genetic TTR variant Val122Ile (or V122I). He is an investigator on numerous NIH-funded awards including co-PI of the $7.2m NHLBI-funded Screening for Cardiac Amyloidosis with Nuclear Imaging (SCAN-MP, R01 HL139671) study. An active clinical cardiologist at the BU Amyloidosis Center, he has also contributed and co-directed numerous collaborative clinical guidelines initiatives, mostly recently including in 2023 the ACC Expert Consensus Decision Pathway document on The Comprehensive Multidisciplinary Care of Patient with Cardiac Amyloidosis. Dr. Ruberg has been recognized with mentorship (2017) and citizenship (2022) awards from the BU Department of Medicine.
Omar K. Siddiqi, MD

Dr. Omar K. Siddiqi is a non-invasive cardiologist at Boston Medical Center and the Boston University School of Medicine. He is the Program Director of the Cardiovascular Medicine fellowship at Boston University and an educator at the Boston University School of Medicine. Dr. Siddiqi attends in the cardiac amyloidosis clinic at the Boston University Amyloidosis Center. His research interests include the development and supervision of clinical trials, particularly those testing novel cardiac amyloidosis therapies.
K. H. Vincent Lau, MD

Dr. K. H. Vincent Lau is a neuromuscular amyloidosis specialist at Boston University School of Medicine. He is also the outpatient medical director for the department of neurology. He joined the Amyloidosis Center after completing a neurology residency program at Yale-New Haven Hospital and neuromuscular fellowship program at Harvard-Mass General Brigham. His research in hereditary amyloidosis, specifically on neurofilament light chain as a biomarker for neuropathy, is supported by the Amyloidosis Foundation.
Michelle Kaku, MD

Michelle Kaku, MD is an Assistant Professor of Neurology and neuromuscular specialist at the Boston University School of Medicine. She has a special interest in neurologic manifestations of Amyloidosis, as well as small fiber neuropathy, and myasthenia gravis. She has been part of the Amyloidosis Center at BU for the past 6 years and has participated in several Amyloidosis clinical trials. She has also served as Program Director to the Neurology Residency for the past 4 years.

Thank you

Description

Contributors

Frederick L. Ruberg, MD

Omar K. Siddiqi, MD

K. H. Vincent Lau, MD

Michelle Kaku, MD